Drug intelligence / Profile preview

PC-0061

Development stage
Preclinical
Lead developer
Changtai Pharmaceutical
Modality
Small Molecules
Administration
Intramuscular
01

Overview

PC-0061 is a long-acting microsphere injection formulation of **naltrexone**, a small molecule opioid receptor antagonist. Developed by **Changtai Pharmaceutical** (also known as **PharmaMax Corp**), it is specifically designed for the treatment of **opioid dependence** and **alcohol dependence**. The drug utilizes a microsphere delivery system to provide sustained release of the active ingredient over an extended period, typically one month, following a single intramuscular injection. This long-acting formulation aims to improve patient compliance and treatment outcomes by eliminating the need for daily oral dosing, which is a significant challenge in addiction recovery. Naltrexone works by competitively binding to mu-opioid receptors in the central nervous system, thereby blocking the euphoric and reinforcing effects of exogenous opioids and reducing alcohol cravings by modulating the brain's reward pathways.

Other names
naltrexone microspheresnaltrexone long-acting injection
02

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on PC-0061.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PC-0061.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call